CA2269656A1 - Peptide natriuretique cerebral (bnp) specifique pour un recepteur - Google Patents

Peptide natriuretique cerebral (bnp) specifique pour un recepteur Download PDF

Info

Publication number
CA2269656A1
CA2269656A1 CA002269656A CA2269656A CA2269656A1 CA 2269656 A1 CA2269656 A1 CA 2269656A1 CA 002269656 A CA002269656 A CA 002269656A CA 2269656 A CA2269656 A CA 2269656A CA 2269656 A1 CA2269656 A1 CA 2269656A1
Authority
CA
Canada
Prior art keywords
arg
ser
gly
seq
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002269656A
Other languages
English (en)
Inventor
David G. Lowe
Jill R. Schoenfeld
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2269656A1 publication Critical patent/CA2269656A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002269656A 1996-10-22 1997-10-09 Peptide natriuretique cerebral (bnp) specifique pour un recepteur Abandoned CA2269656A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73188096A 1996-10-22 1996-10-22
US08/731,880 1996-10-22
PCT/US1997/018384 WO1998017690A1 (fr) 1996-10-22 1997-10-09 Peptide natriuretique cerebral (bnp) specifique pour un recepteur

Publications (1)

Publication Number Publication Date
CA2269656A1 true CA2269656A1 (fr) 1998-04-30

Family

ID=24941306

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002269656A Abandoned CA2269656A1 (fr) 1996-10-22 1997-10-09 Peptide natriuretique cerebral (bnp) specifique pour un recepteur

Country Status (6)

Country Link
EP (1) EP0939770A1 (fr)
JP (1) JP2001503256A (fr)
AU (1) AU4816497A (fr)
CA (1) CA2269656A1 (fr)
WO (1) WO1998017690A1 (fr)
ZA (1) ZA979060B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004047871A2 (fr) 2002-11-26 2004-06-10 Nobex Corporation Composes natriuretiques modifies, leurs conjugues et leur utilisation
CA2559228C (fr) 2004-04-21 2016-06-21 Enobia Pharma Inc. Conjugues de delivrance dans l'os et procede d'utilisation pour le ciblage de proteines osseuses
WO2012088608A1 (fr) 2010-12-27 2012-07-05 Enobia Canada Limited Partnership Compositions contenant des peptides natriurétiques et leurs méthodes d'utilisation
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2016007873A1 (fr) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions et méthodes de traitement de la craniosynostose
MX389350B (es) 2014-12-05 2025-03-19 Alexion Pharma Inc Fosfatasas alcalinas recombinantes y usos de las mismas para el tratamiento de convulsiones.
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
CN108350440A (zh) 2015-08-17 2018-07-31 阿雷克森制药公司 碱性磷酸酯的制造
JP6868617B2 (ja) 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定
JP2018533571A (ja) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の頭蓋縫合早期癒合症を治療するための方法
WO2017155569A1 (fr) 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Méthodes de traitement de l'hypophosphatasie chez l'enfant
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
JP7613826B2 (ja) 2016-04-01 2025-01-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼによって筋力低下を治療すること
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
EP3500289B1 (fr) 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa le traitement de la trachéobronchomalacie
EP3600383A4 (fr) 2017-03-31 2020-10-28 Alexion Pharmaceuticals, Inc. Méthodes de traitement de l'hypophosphatasie (hpp) chez l'adulte et l'adolescent
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
US12268733B2 (en) 2018-08-10 2025-04-08 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
CA3161266A1 (fr) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Polypeptides de phosphatase alcaline et leurs procedes d'utilisation
AU2021337652B2 (en) 2020-09-04 2025-01-30 Alexion Pharmaceuticals, Inc. Methods for treating bone mineralization disorders
BR112023016048A2 (pt) 2021-02-12 2023-11-14 Alexion Pharma Inc Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69432123T2 (de) * 1993-11-12 2004-01-08 Genentech, Inc., South San Francisco Rezeptor spezifische atrio-natriuretische peptide

Also Published As

Publication number Publication date
WO1998017690A1 (fr) 1998-04-30
EP0939770A1 (fr) 1999-09-08
JP2001503256A (ja) 2001-03-13
ZA979060B (en) 1999-04-09
AU4816497A (en) 1998-05-15

Similar Documents

Publication Publication Date Title
US6028055A (en) Receptor selective BNP
US5846932A (en) Receptor specific atrial natriuretic peptides
US5665704A (en) Receptor specific atrial natriuretic peptides
EP0728147B1 (fr) Peptides natriuretiques auriculaires specifiques d'un recepteur
US6525022B1 (en) Receptor specific atrial natriuretic peptides
CA2269656A1 (fr) Peptide natriuretique cerebral (bnp) specifique pour un recepteur
US5583108A (en) Vasonatrin peptide and analogs thereof
US6025467A (en) Parathyroid hormone derivatives and their use
AU632043B2 (en) Cyclic analogs of atrial natriuretic peptides
US4607023A (en) Natriuretic
EP0543425B1 (fr) ADN de l'endothéline et son utilisation
JPH05255392A (ja) Ａ−ｃ−ｂプロインスリン、その製造法および使用法、およびインスリン生産の中間体
US4939224A (en) Vasoactive intestinal peptide analogs
EP1709065A2 (fr) Processus d'echange de contre-ion pour peptides
JPH0690780A (ja) ヒト−レラキシン遺伝子
JP4166289B2 (ja) 環式ｃｒｆアゴニスト
Sohma et al. Comparative properties of insulin-like growth factor 1 (IGF-1) and [Gly7D-Ala] IGF-1 prepared by total chemical synthesis
AU8237187A (en) Derivatives of atrial natriuretic peptides
JPH0725799B2 (ja) 高カルシウム体液性因子拮抗薬
EP0315118A2 (fr) ADN codant pour endothéline et son utilisant
US20170333530A1 (en) Methods and materials for reducing cysts and kidney weight in mammals with polycystic kidney disease
WO1992014834A1 (fr) Proteine de liaison du facteur de croissance proche de l'insuline
Morris et al. Synthesis of mouse renin as a 2‐5‐33‐5 kilodalton pre‐pro‐two‐chain molecule and use of its cDNA to identify the human gene
JPH09157294A (ja) 副甲状腺ホルモン誘導体
DK2209798T3 (en) modified væksthormonpolypeptider

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead